we see cancer differently

the power of clarity

Epic Sciences tests for longevity, not just biology. Our groundbreaking, unbiased approach, Functional Cell Profiling (FCP) liquid biopsy platform, sees those rare cells that others miss. By peering more deeply into the single cell, we can perceive both genotype and phenotypes together, uncovering the heterogeneity and delivering tests that are personalized, predictive and proven. We give cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy, in days rather than weeks or months. 

The cell holds the answers,
And our tests unlock those answers to extend lives.

functional cell
profiling (FCP)

Essential to detecting and understanding cancer heterogeneity, Epic Sciences' groundbreaking circulating tumor cell (CTC) detection engine, FCP, analyzes all nucleated cells within a blood sample at single cell resolution. Our platform also allows us to characterize immune cell subsets which has great potential in predicting response in immunomodulators.

learn more

ar-v7 test

The AR-V7 test is the first and only Medicare reimbursed, clinically-validated, predictive circulating tumor cell (CTC) liquid biopsy test for metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies.

learn more

decision point

For pharmaceutical and clinical investigation partners, our Decision Point program delivers a bias-free approach for cancer research, to develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity.

19

cancer
types

45

academic
partners

65

pharmaceutical
partners

23

publications

>200

clinical trials

>30,000

single CTC genomes sequenced

>80,000

patient samples contracted

view our solutions

What sources are saying

Read the articles

Epic Sciences is creating a breakthrough new category of cancer diagnostics.

Of the roughly 50 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics can’t see them, but we can.